Telehealth Reviews
RxFemale Review 2026: Is the Budget GLP-1 Program Legit?
RxFemale is a real, functioning women's telehealth program selling compounded semaglutide and tirzepatide from an advertised $129.99/month — roughly the cheapest credible entry point to GLP-1 treatment. It is also a compounded-medication program in the middle of the FDA's 2026 crackdown, and parts of its marketing overreach the evidence. This review covers both halves honestly — including the things its landing page won't tell you.
What RxFemale is
RxFemale is the women's brand of a US telehealth weight-loss operator (its sibling brand, GuysMeds, serves men). The offer: a fully online medical intake, prescription and telemedicine visit included in the price, compounded semaglutide or tirzepatide shipped to your door, no insurance required. Advertised pricing starts at $129.99/month with a same-price-every-dose policy — an honest structural plus, since some competitors' prices climb as your dose escalates.
Where the marketing overreaches
We compared RxFemale's advertised claims against the clinical trials, as we do for every program:
| The claim | What the evidence says |
|---|---|
| "Lose 15% – 25% of your body weight fast!" | The 15% end matches semaglutide's trial average — over 68 weeks (STEP 1: 14.9%). The 25% end reflects the best responders on tirzepatide's highest dose (SURMOUNT-1 average: 20.9% at 72 weeks). "Fast" is the word doing the misleading — these are 16-month averages. |
| Weight-by-summer calculator ("You could easily lose 44 lbs") | No trial supports a pounds-by-date promise; the FTC's false-claims guide flags exactly this pattern. Treat the calculator as marketing theater. |
| "Safe & Effective Medications" | The molecules are trial-proven; but compounded versions of them are not FDA-approved products, which is a real distinction the phrase papers over — see below. |
The regulatory elephant: it's compounded
This is the part any honest review must lead with. RxFemale sells compounded GLP-1s: pharmacy-made versions that are not FDA-approved, in a category where the FDA has logged 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026 (many from dosing errors), sent warning letters to 30 telehealth companies in March 2026, and is moving to close large-scale compounding. Two practical consequences: the specific product you receive has not been through FDA review, and the whole compounded supply channel could shrink or vanish with little notice. Our full explainer: compounded vs branded in 2026.
Who it's a rational choice for
If branded medication at several hundred dollars a month simply isn't happening for you, a roughly $130/month program is the difference between treating and not treating — and that's a legitimate calculus if you go in with open eyes: know the product is compounded, keep a continuity plan for switching to a branded option, and treat any results promise faster than the trial timelines as noise. If budget allows branded medication, our program comparison covers six settled alternatives.